TABLE 1.
Enrolled Patient Demographics, Characteristics, and Coronavirus Disease 2019 Therapies
| Characteristic | IV Immunoglobulin (n = 16) | Standard of Care (n = 17) |
|---|---|---|
| Mean age (yr) | 54 | 54 |
| Median age (yr) | 58 | 51 |
| Male, n (%) | 10 (63) | 10 (59) |
| Ethnicity, n (%) | ||
| Hispanic/Latino | 13 (81) | 15 (88) |
| White | 3 (19) | 2 (12) |
| Mean body mass index | 32.8 | 34.8 |
| Comorbidities | ||
| Diabetes mellitus, n (%) | 6 (38) | 6 (35) |
| Mean HgbA1c, % | 10.1 | 6.4 |
| Hypertension, n (%) | 4 (25) | 7 (41) |
| Chronic kidney disease, n (%) | 0 (0) | 1 (6) |
| Coronary artery disease, n (%) | 1 (6) | 1 (6) |
| Congestive heart failure, n (%) | 1 (6) | 1 (6) |
| Asthma/chronic obstructive pulmonary disease, n (%) | 2 (12) | 2 (12) |
| Current smoker, n (%) | 1 (6) | 1 (6) |
| Former smoker, n (%) | 2 (12) | 1 (6) |
| Immunocompromised, n (%) | 1 (6) | 0 (0) |
| Other coronavirus disease 2019 therapies, n (%) | ||
| Remdesivir | 8 (50) | 9 (53) |
| Convalescent plasma | 2 (12) | 3 (18) |
| Glucocorticoids | 16 (100) | 10 (59) |
aAll IV Immunoglobulin patients received at least methylprednisolone 40 mg IV 30–60 min before each dose (3 d) per protocol.